The smart ring has become a serious business. Oura, the Finnish health-tracking wearable company best known for the ring you wear instead of the watch you forget to charge, is eyeing a September IPO that could value it at more than $16 billion, according to a TechCrunch report citing people familiar with the matter. If that number holds, Oura would rank among the most valuable wearable health tech companies ever to hit public markets — and it would do it on the strength of a piece of hardware you can barely see on someone’s finger.
The timing is aggressive. September IPOs live and die by the window between summer doldrums and fourth-quarter volatility, and Oura is clearly betting the market appetite for health tech and AI-driven wellness data is strong enough to absorb a listing at this scale. For context on what ambitious tech debuts look like right now, it’s worth noting that even high-profile listings like the public market debut have drawn intense scrutiny over valuation versus fundamentals — Oura will face the same questions.
From Niche Gadget to $16 Billion Platform
Oura has spent years quietly building a subscriber base and a hardware line that now competes directly with Apple, Samsung, and Garmin in the continuous health monitoring space. The Oura Ring tracks sleep stages, resting heart rate, heart rate variability, body temperature, respiratory rate, and activity — and it packages all of that into a readiness score that has become something of a cult metric among athletes, executives, and biohackers. The company charges a monthly subscription fee on top of the hardware cost, which gives it recurring revenue that pure device makers don’t have.
That subscription layer is almost certainly what’s driving the $16 billion figure. Hardware alone doesn’t command that multiple. But a platform that owns daily health data for millions of users, with the infrastructure to layer in AI-powered insights over time, is a different story entirely. Oura has already begun expanding its health intelligence features, positioning the ring not just as a tracker but as a longitudinal health record on your finger. That framing — wearable as medical-adjacent platform — is where the real valuation argument lives. It also dovetails with a broader industry push toward personalized health monitoring, an area where companies like Sonova are making aggressive AI bets, as seen in AI health platform rollout.
What the IPO Will Actually Prove
A $16 billion valuation is a statement, but public markets will want to see the numbers underneath it. Oura has not disclosed its revenue or subscriber count publicly ahead of the filing, but analysts will be looking hard at its annualized recurring revenue from subscriptions, its hardware margins, and its churn rate. The smart ring market is no longer uncrowded — Samsung launched its Galaxy Ring in 2024 and has been pushing it aggressively as part of its health ecosystem, while Apple continues to expand Apple Watch health capabilities that overlap significantly with what Oura does.
The IPO will also be a test of investor appetite for health-data businesses that sit in an ambiguous regulatory space. Oura’s metrics are not FDA-cleared diagnostic tools, which limits liability but also limits the premium it can command from healthcare payers and enterprise clients. Going public forces that tension into the open. If the company prices above $16 billion and trades up on debut, it validates the thesis that subscription-driven wearables are the next major platform category. If it stumbles, it becomes a cautionary data point for every digital health company watching from the sidelines. Either way, September is going to be clarifying.
